Effects of Transcranial direct currency stimulation (tDCS) on the treatment of depressive and anxiety symptoms and improve quality of sleep in patients with chronic renal diseases on dialysis

Effects of Transcranial direct-current stimulation (tDCS) on the treatment of depressive and anxiety symptoms and improve quality of sleep in patients with chronic renal diseases on dialysis- a randomized double-blind placebo controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017020311885N8

Enrollment

Registered

2017-04-01

Start date

2015-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal diseases. Chronic kidney disease

Interventions

Intervention 1: In main intervention, Subject of two "anxiety and depression" and "sleep disorders" groups were under tDCS.F3-Fp2 protocol was used in main intervention group according to 10-20 system

Treatment - Devices

In main intervention, Subject of two "anxiety and depression" and "sleep disorders" groups were under tDCS.F3-Fp2 protocol was used in main intervention group according to 10-20 system of regions of t

in placebo group, Subject of two "anxiety and depression" and "sleep disorders" groups were under tDCS.F3-Fp2 protocol was used in main intervention group according to 10-20 system of regions of the b

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: History of head trauma in patient; history of epilepsy in patients or their families; past history of bipolar dx. or psychotic dx.; acute suicidal ideas; consumption of neuroleptics during the study; addiction to drugs or alcohol; pregnancy; having metal prosthesis or implant; severe anorexia; past history of neurologic dx. , serious medical illness.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Anxiety, depression. Timepoint: Before intervention, after 15 sessions of intervention and 10 days after the end of inervention. Method of measurement: HADS questionnaire.;Sleep quality. Timepoint: Before intervention, after 15 sessions of intervention and 10 days after the end of inervention. Method of measurement: PSQI questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamaneh Farnia

Mazandaran University of Medical Sciences

sfarnia@mazums.ac.ir+98 11 3326 2646

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026